Association of body mass index with risk of acute myocardial infarction and mortality in Norwegian male and female patients with suspected stable angina pectoris: a prospective cohort study

  • Heidi Borgeraas1, 2, 3Email author,

    Affiliated with

    • Jens Kristoffer Hertel1,

      Affiliated with

      • Gard Frodahl Tveitevåg Svingen3,

        Affiliated with

        • Reinhard Seifert4,

          Affiliated with

          • Eva Kristine Ringdal Pedersen3,

            Affiliated with

            • Hall Schartum-Hansen4,

              Affiliated with

              • Jøran Hjelmesæth1, 2Email author and

                Affiliated with

                • Ottar Nygård3, 4Email author

                  Affiliated with

                  BMC Cardiovascular Disorders201414:68

                  DOI: 10.1186/1471-2261-14-68

                  Received: 21 November 2013

                  Accepted: 16 May 2014

                  Published: 21 May 2014

                  Abstract

                  Background

                  A number of previous studies have suggested that overweight or obese patients with coronary artery disease (CAD) may have lower morbidity and mortality than their leaner counterparts. Few studies have addressed possible gender differences, and the results are conflicting. We examined the association between body mass index (BMI) and risk of acute myocardial infarction (AMI), cardiovascular (CV) death and all-cause mortality in men and women with suspected stable angina pectoris.

                  Method

                  The cohort included 4164 patients with suspected stable angina undergoing elective coronary angiography between 2000 and 2004. Events were registered until the end of 2006. Hazard ratios (HR) (95% confidence intervals) were estimated using Cox regression by comparing normal weight (18.5-24.9 kg/m2) with overweight (25–29.9 kg/m2) and obese (≥30 kg/m2) patients. Underweight (<18.5 kg/m2) patients were excluded from the study.

                  Results

                  Of 4131 patients with complete data, 72% were males and 75% were diagnosed with significant CAD. The mean (standard deviation (SD)) age in the total population was 62 (10) years. Mean (SD) BMI was 26.8 (3.9) kg/m2, 34% was normal weight, 48% overweight and 19% obese. During follow up, a total of 337 (8.2%) experienced an AMI and 302 (7.3%) patients died, of whom 165 (4.0%) died from cardiovascular causes. We observed a significant interaction between BMI groups and gender with regards to risk of AMI (p = 0.011) and CV death (p = 0.031), but not to risk of all-cause mortality; obese men had a multivariate adjusted increased risk of AMI (HR 1.80 (1.28, 2.52)) and CV death (HR 1.60 (1.00, 2.55)) compared to normal weight men. By contrast, overweight women had a decreased risk of AMI (HR 0.56 (0.33, 0.98)) compared to normal weight women. The risk of all-cause mortality did not differ between BMI categories.

                  Conclusion

                  Compared with normal weight subjects, obese men had an increased risk of AMI and CV death, while overweight women had a decreased risk of AMI. These findings may potentially explain some of the result variation in previous studies reporting on the obesity paradox.

                  Trial registration

                  Clinicaltrials.gov Identifier: NCT00354081

                  Keywords

                  Acute myocardial infarction Body mass index Cardiovascular disease Obesity paradox

                  Background

                  Cardiovascular disease (CVD) is the leading cause of death globally: the majority dying from ischemic heart disease [1]. Overweight and obesity, most commonly defined according to body mass index (BMI), has been characterized as a major modifiable risk factor for cardiovascular (CV) morbidity and mortality by the American Heart Association and the American College of Cardiology [2].

                  As recently reviewed, some studies of patients with coronary artery disease (CAD) suggest that being overweight or obese has beneficial effects in terms of reduced risk of CV events and/or mortality; a phenomenon known as the obesity paradox. However, there is no broad consensus regarding the obesity paradox, as several studies are unsupportive of this conclusion [3].

                  Moreover, despite the fact that both body fat percentage and distribution vary by gender [4], only a limited number of studies among patients with CAD or suspected CAD have examined the association between BMI and risk of coronary events and mortality in men and women separately, and the reported results are conflicting [59]. There is, however, a tendency towards a non-disadvantageous [5, 6, 9] or even a beneficial [7] effect of overweight and obesity among women, while obesity appears to increase the risk of coronary events in men [5, 6].

                  In the present study we examined the association between BMI and risk of incident acute myocardial infarction (AMI), CV death and all-cause mortality in a large population of men and women with suspected CAD. We hypothesized that overweight and/or obesity, as compared to normal weight, was associated with an increased risk of AMI, CV death and all-cause mortality among men, but not among women.

                  Methods

                  Study design and patient population

                  The patients recruited for the present investigation are described in detail elsewhere [10]. In brief, 4164 patients undergoing elective coronary angiography for suspected stable angina pectoris were recruited from two university hospitals in Western Norway from January 2000 to April 2004. Of these patients, 2573 (62.0%) were enrolled in the Western Norway B Vitamin Intervention Trial (WENBIT) which studied the prognostic impact of B-vitamin supplementation upon incident CV events and mortality (clinicaltrials.gov Identifier: NCT00354081) [11]. Patients for whom there was no BMI data (n = 3) were excluded from the study, as were underweight patients (BMI < 18.5 kg/m2) (n = 30).This left a total of 4131 subjects eligible for the analyses.

                  The study protocol met the mandate of the Helsinki Declaration, and was approved by the Western Norway Regional Committee for Medical and Health Research Ethics and the Norwegian Data Inspectorate. Written informed consent was obtained from all participants.

                  Baseline data and biochemical analyses

                  Height, weight and blood pressure were measured at baseline by trained study personnel. BMI was calculated by dividing weight by height squared (kg/m2). Each patient provided information about medical history, risk factors and medications through a self-administered questionnaire, and all information was subsequently validated against medical records. Diabetes mellitus included type 1 and 2. Current smokers included those with self-reported current smoking, those who had quit smoking within <1 month and those with plasma cotinine >85 ng/mL [12]. Patients, who reported to have quit smoking > 1 month prior to inclusion and had plasma cotinine levels ≤85 ng/mL, were categorized as ex-smokers. Pulmonary disease included chronic obstructive lung disease, other chronic lung diseases and pulmonal hypertension. Cancer included active cancer with or without metastases. Family history of early coronary heart disease (CHD) encompassed those reporting to have at least one 1st degree relative suffering from CHD before the age of 55 for men and 65 for women. Left ventricular ejection fraction (LVEF) was determined by ventriculography or echocardiography. The extent of CAD at angiography was scored as 0–3 as has previously been described [11]. Baseline coronary revascularisation procedures, after baseline angiography, included percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG).

                  Blood samples were collected by study personnel prior to angiography and stored at -80˚C until analysis. Serum apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB) and lipoprotein (a) (Lp(a)) were analysed on the Hitachi 917 system (Roche Diagnostics, GmbH, Mannheim, Germany). Serum C-reactive protein (CRP) was measured using a latex, high sensitive assay (Behring Diagnostics, Marburg, Germany). Plasma cotinine was measured by liquid chromatography/tandem mass spectrometry [13]. Low density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula [14] and estimated glomerular filtration rate (eGFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration formula [15].

                  Follow-up and end points

                  The study participants were followed from angiography until they experienced one of the primary endpoints; AMI (fatal or non-fatal), death or till December 31st 2006.

                  Information on clinical events was collected from The Western Norway Cardiovascular Registry and from the Cause of Death Registry at Statistics Norway as previously described [11]. An event was classified as fatal if death occurred within 28 days after onset. AMI was classified according to the diagnostic criteria of the revised AMI definition published in 2000 [16], and fatal strokes were classified according to diagnostic criteria published in 2001 [17]. Procedure-related non-fatal AMI occurring within 24 h of coronary angiography, PCI or CABG were not included in the end-point. CV death included causes of death coded I00-I99 or R96, according to the International Statistical Evaluation of Disease, Tenth Revision system. An endpoints committee adjudicated all events.

                  Statistical analysis

                  Continuous variables are presented as means (standard deviation (SD)). Categorical variables are reported as counts (percentage). Non-normally distributed variables (diastolic blood pressure, serum creatinine, CRP, plasma glucose, serum triglycerides and Lp(a)) were log transformed. BMI groups were created using established BMI cut-offs; Normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obesity (BMI ≥30 kg/m2). Underweight patients (n = 30) were eliminated due to the possibility of reverse causation. Between group differences were tested by one-way analysis of variance (ANOVA) or independent samples t-test for continuous variables, and by chi square test for categorical variables. Post hoc tests were applied for multiple comparisons where appropriate.

                  The relationships between baseline BMI and subsequent risk of AMI, CV death and all-cause mortality were evaluated across BMI groups. Hazard ratios (HR) and 95% confidence intervals (CI) of endpoints associated with BMI categories were estimated with Cox proportional hazard models using the BMI normal weight category as reference. The time, in days, from angiography until endpoint (AMI, CV death and all-cause mortality) or end of study (December 31st 2006) was used as time scale. Proportionality assumptions were tested by visual examination of log minus log plots and calculating Schoenfeld residuals. Covariates in the multivariate adjusted models were selected based on clinical relevance and the change-in-estimate method [18], with a limit for inclusion of 10% change in the risk ratio. The final multivariate model included gender, age (continuous), LVEF (%), current smoking (yes/no), angiotensin converting enzyme (ACE) -inhibitors (yes/no), loop diuretics (yes/no) and pulmonary disease (yes/no). Further adjustment of the multivariate Cox model did not alter the results in the total population or in gender stratified analyses; systolic and diastolic blood pressure (mmHg), diabetes mellitus (yes/no), previous AMI (yes/no), extent of significant CAD (0–3), serum creatinine levels (μmol/L), CRP (mg/L), total cholesterol (mmol/L), vitamin B6 (yes/no) or folate/B12 (yes/no) intervention status (data not shown).

                  Effect modifications by gender were investigated by including the product of gender and BMI categories as an interaction term in the multivariate adjusted Cox model.

                  All tests were 2-sided, and a p-value <0.05 was considered significant. Statistical analyses were performed with SPSS 17 (SPSS Inc, Chicago, IL) and R 2.14.2 (The R-Foundation for Statistical Computing, Vienna, Austria).

                  Results

                  Baseline characteristics

                  The cohort consisted of 4131 patients (72% males), and the mean (SD) age in the total population was 62 (10) years. Baseline characteristics across BMI groups are presented in Table  1. The mean (SD) BMI was 26.8 (3.9) kg/m2, and 34% of the patients had a BMI within the normal weight range, 48% were overweight and 19% were obese.
                  Table 1

                  Baseline characteristics and laboratory findings according to BMI groups a

                   

                  Total n = 4131

                  Normal weight n = 1395

                  Overweight n = 1970

                  Obese n = 766

                  p-valueb

                  Demographic characteristics

                       

                  Male sex, n (%)

                  2989 (72.4)

                  959 (68.7)

                  1517 (77.0)

                  513 (67.0)

                  <0.001

                  Age (years)c

                  62 (10)

                  63 (11)

                  61 (10)

                  60 (10)

                  <0.001

                  Clinical parameters

                       

                  Systolic blood pressure (mmHg)

                  141 (20.7)

                  139 (21.0)

                  142 (20.6)

                  143 (20.3)

                  <0.001

                  Diastolic blood pressure (mmHg)

                  81.3 (10.4)

                  79.3 (10.3)

                  82.0 (10.1)

                  83.3 (10.7)

                  <0.001

                  Left ventricular ejection fraction (%)

                  64.0 (11.3)

                  63.7 (11.9)

                  64.4 (10.7)

                  63.6 (11.8)

                  0.08

                  Cardiovascular risk factors, n (%)

                       

                  Diabetesd

                  496 (12.0)

                  123 (8.8)

                  209 (10.6)

                  164 (21.4)

                  <0.001

                  Current smokere

                  1061 (25.7)

                  417 (29.9)

                  469 (23.9)

                  175 (22.9)

                  <0.001

                  Ex smokerf

                  1933 (46.9)

                  571 (40.6)

                  975 (49.6)

                  387 (50.7)

                  <0.001

                  Family history of coronary heart diseaseg

                  1253 (31.1)

                  417 (30.8)

                  573 (29.7)

                  263 (35.1)

                  0.02

                  Cardiovascular history, n (%)

                       

                  Previous acute myocardial infarction

                  1670 (40.4)

                  564 (40.4)

                  784 (39.8)

                  322 (42.0)

                  0.56

                  Previous cerebrovascular disease

                  286 (6.9)

                  100 (7.2)

                  128 (6.5)

                  58 (7.6)

                  0.55

                  Previous peripheral vascular arterial disease

                  371 (9.0)

                  153 (11.0)

                  148 (7.5)

                  70 (9.1)

                  <0.01

                  Previous percutaneous coronary intervention

                  794 (19.2)

                  250 (17.9)

                  396 (20.1)

                  148 (19.3)

                  0.29

                  Previous coronary artery bypass graft surgery

                  477 (11.5)

                  150 (10.8)

                  238 (12.1)

                  89 (11.6)

                  0.49

                  Extent of coronary artery disease at baseline as assessed by coronary angiography, n (%)

                     

                  No significant coronary artery disease

                  1030 (24.9)

                  367 (26.3)

                  467 (23.7)

                  196 (25.6)

                  0.21

                  1-vessel disease

                  958 (23.2)

                  306 (21.9)

                  482 (24.5)

                  170 (22.2)

                  0.18

                  2-vessel disease

                  923 (22.3)

                  308 (22.1)

                  440 (22.3)

                  175 (22.8)

                  0.92

                  3-vesseldisease

                  1220 (29.5)

                  414 (29.7)

                  581 (29.5)

                  225 (29.4)

                  0.99

                  Comorbidity at baseline, n (%)

                       

                  Pulmonary disease

                  367 (8.9)

                  139 (10.0)

                  140 (7.1)

                  88 (11.5)

                  <0.001

                  Cancer

                  4 (0.1)

                  2 (0.1)

                  1 (0.1)

                  1 (0.1)

                  0.66

                  Medication following baseline coronary angiography, n (%)

                      

                  Acetylsalisylic acid

                  3376 (81.7)

                  1114 (79.9)

                  1638 (83.1)

                  624 (81.5)

                  0.05

                  Statins

                  3310 (80.1)

                  1064 (76.3)

                  1626 (82.5)

                  620 (80.9)

                  <0.001

                  β-blockers

                  2994 (72.5)

                  970 (69.5)

                  1456 (73.9)

                  568 (74.2)

                  0.01

                  ACE inhibitors

                  858 (20.8)

                  243 (17.4)

                  403 (20.5)

                  212 (27.7)

                  <0.001

                  Loop diuretics

                  447 (10.8)

                  127 (9.1)

                  182 (9.2)

                  138 (18.0)

                  <0.001

                  Coronary revascularization following baseline coronary angiography, n (%)

                     

                  Percutaneous coronary intervention

                  1348 (32.6)

                  432 (31.0)

                  663 (33.7)

                  253 (33.0)

                  0.26

                  Coronary artery bypass graft surgery

                  892 (21.6)

                  302 (21.6)

                  438 (22.2)

                  152 (19.8)

                  0.39

                  Biochemical markers

                       

                  Creatinine (μmol/L)

                  92.6 (31.1)

                  92.5 (33.4)

                  93.0 (32.0)

                  91.8 (23.4)

                  0.34

                  eGFR (mL/min)

                  87.8 (17.3)

                  86.2 (17.7)

                  88.5 (16.6)

                  88.9 (17.8)

                  <0.001

                  CRP (mg/L)

                  3.69 (7.17)

                  3.34 (7.93)

                  3.59 (6.67)

                  4.60 (6.85)

                  <0.001

                  Glucose (mmol/L)

                  6.35 (2.40)

                  5.93 (2.24)

                  6.32 (2.28)

                  7.20 (2.79)

                  <0.001

                  HbA1c (mmol/L)

                  6.22 (1.38)

                  6.12 (1.28)

                  6.18 (1.41)

                  6.51 (1.45)

                  <0.001

                  Hemoglobin (g/dL)

                  14.2 (1.24)

                  13.9 (1.24)

                  14.4 (1.18)

                  14.4 (1.29)

                  <0.001

                  ApoA1 (g/L)

                  1.32 (0.27)

                  1.37 (0.29)

                  1.30 (0.25)

                  1.27 (0.26)

                  <0.001

                  ApoB (g/L)

                  0.90 (0.25)

                  0.87 (0.24)

                  0.91 (0.24)

                  0.93 (0.26)

                  <0.001

                  Total cholesterol (mmol/L)

                  5.07 (1.17)

                  5.02 (1.14)

                  5.08 (1.18)

                  5.10 (1.19)

                  0.13

                  LDL cholesterol (mmol/L)

                  3.09 (1.03)

                  3.05 (1.02)

                  3.12 (1.00)

                  3.11 (1.10)

                  0.11

                  HDL cholesterol (mmol/L)

                  1.29 (0.38)

                  1.42 (0.43)

                  1.25 (0.34)

                  1.17 (0.32)

                  <0.001

                  Triglycerides (mmol/L)

                  1.78 (1.22)

                  1.43 (0.90)

                  1.86 (1.28)

                  2.22 (1.39)

                  <0.001

                  Lp(a) (mmol/L)

                  0.42 (0.39)

                  0.41 (0.39)

                  0.43 (0.39)

                  0.42 (0.39)

                  0.03

                  WENBIT intervention trial, n (%)

                  2560 (62.0)

                  797 (57.1)

                  1283 (65.1)

                  480 (62.7)

                  <0.001

                  B6, n (% of WENBIT participants)

                  1275 (49.8)

                  394 (49.4)

                  657 (51.2)

                  224 (46.7)

                  <0.01

                  Folate/B12, n (% of WENBIT participants)

                  1282 (50.1)

                  409 (51.3)

                  649 (50.6)

                  224 (46.7)

                  0.04

                  ACE, angiotensin converting enzyme; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, body mass index; CRP, c-reactive protein; eGFR, esitimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; Lp(a), lipoprotein (a).

                  aNormal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2).

                  bBased on between group differences calculated by one-way analysis of variance (ANOVA) for continuous variables and Chi squared test for categorical variables.

                  cMean (SD).

                  dIncludes DM type 1 and 2.

                  eSmokers included self-reported current smoking, those who quit smoking within <1 month and patients with plasma cotinine >85 ng/mL.

                  fPatients reported to have quit smoking > 1 month prior to inclusion.

                  gIncluded those reporting to have at least one 1st degree relative suffering from CAD before the age of 55 for men and 65 for women.

                  Compared to the overweight and obese groups, the normal weight group was characterised by older age and a higher proportion of current smokers and subjects with a history of peripheral arterial disease. Mean blood pressure was lower in this group, as was the prevalence of diabetes. The extent of CAD at baseline did, however, not differ between the BMI categories. Compared to normal weight patients, overweight and obese patients were more often discharged with aspirin, statins and beta-blockers, while ACE inhibitors and loop diuretics were more often prescribed to obese patients.

                  The levels of eGFR, serum CRP, plasma glucose, HbA1c, Hb, serum ApoB, triglyceride and Lp(a) increased across incremental BMI groups, while serum ApoA1 and HDL cholesterol levels declined.

                  Baseline characteristics according to gender

                  Among men, 32% were normal weight, 51% overweight and 17% obese, whereas the respective proportions were 38%, 40% and 22% among women. Mean (SD) BMI was 26.8 (3.7) kg/m2 among men and 26.8 (4.7) kg/m2 among women.

                  Baseline characteristics according to gender and BMI groups are presented in Table  2. Compared to women, men were generally younger, and there was an inverse relationship between age and BMI among men. Men had worse CV risk profile and more severe CAD, at baseline, than women. Correspondingly, men, compared to women, did more often undergo revascularisation procedures following baseline angiography and were more often discharged with medication.
                  Table 2

                  Baseline characteristics and laboratory findings according to gender and BMI groups a

                   

                  Men

                   

                  Women

                    
                   

                  Total

                  Normal weight

                  Overweight

                  Obese

                   

                  Total

                  Normal weight

                  Overweight

                  Obese

                    
                   

                  n = 2989

                  n = 959

                  n = 1517

                  n = 513

                  p-valueb

                  n = 1142

                  n = 436

                  n = 453

                  n = 253

                  p-valuec

                  p-valued

                  Demographic characteristics

                           

                  Age (years)e

                  61 (10)

                  63 (11)

                  61 (10)

                  59 (10)

                  <0.001

                  63 (10)

                  63 (19)

                  64 (11)

                  63 (10)

                  0.52

                  <0.001

                  Clinical parameters

                            

                  Systolic blood pressure (mmHg)

                  141 (20.4)

                  140 (20.5)

                  141 (20.3)

                  143 (20.4)

                  0.03

                  141 (21.6)

                  138 (22.1)

                  143 (21.6)

                  144 (20.2)

                  <0.01

                  0.94

                  Diastolic blood pressure (mmHg)

                  81.8 (10.4)

                  79.6 (10.1)

                  82.2 (10.0)

                  84.3 (11.1)

                  <0.001

                  80.0 (10.3)

                  78.4 (10.8)

                  80.9 (10.1)

                  81.0 (9.60)

                  <0.001

                  <0.001

                  Left ventricular ejection fraction (%)

                  63.1 (11.8)

                  62.6 (12.4)

                  63.7 (11.1)

                  62.1 (12.4)

                  <0.01

                  66.5 (9.81)

                  65.9 (10.3)

                  66.9 (9.21)

                  66.8 (9.93)

                  0.30

                  <0.001

                  Cardiovascular risk factors, n (%)

                           

                  Diabetesf

                  361 (12.1)

                  97 (10.1)

                  158 (10.4)

                  106 (20.7)

                  <0.001

                  135 (11.8)

                  26 (6.0)

                  51 (11.3)

                  58 (22.9)

                  <0.001

                  0.82

                  Current smokerg

                  803 (26.9)

                  305 (31.8)

                  375 (24.8)

                  123 (24.0)

                  <0.001

                  258 (22.7)

                  112 (25.7)

                  94 (20.8)

                  52 (22.7)

                  0.16

                  <0.01

                  Ex smokerh

                  1595 (53.4)

                  448 (46.7)

                  842 (55.6)

                  305 (59.6)

                  <0.001

                  338 (29.7)

                  123 (28.2)

                  133 (29.5)

                  82 (32.7)

                  0.47

                  <0.001

                  Family history of coronary heart diseasei

                  844 (29.0)

                  258 (27.8)

                  417 (28.1)

                  169 (33.9)

                  0.03

                  409 (36.4)

                  159 (37.3)

                  156 (34.9)

                  94 (37.6)

                  0.69

                  <0.001

                  Cardiovascular history, n (%)

                           

                  Previous acute myocardial infarction

                  1346 (45.9)

                  429 (44.7)

                  668 (44.0)

                  249 (48.5)

                  0.20

                  324 (28.4)

                  135 (31.0)

                  116 (25.6)

                  73 (28.9)

                  0.21

                  <0.001

                  Previous cerebrovascular disease

                  203 (6.9)

                  69 (7.2)

                  101 (6.7)

                  33 (6.4)

                  0.82

                  83 (7.3)

                  31 (7.1)

                  27 (6.0)

                  25 (9.9)

                  0.16

                  0.59

                  Previous peripheral vascular arterial disease

                  276 (9.2)

                  114 (11.9)

                  115 (7.6)

                  47 (9.2)

                  <0.01

                  95 (8.3)

                  39 (8.9)

                  33 (7.3)

                  23 (9.1)

                  0.59

                  0.36

                  Previous percutaneous coronary intervention

                  641 (21.4)

                  193 (20.1)

                  340 (22.4)

                  108 (21.1)

                  0.39

                  153 (13.4)

                  57 (13.1)

                  56 (12.4)

                  40 (15.8)

                  0.42

                  <0.001

                  Previous coronary artery bypass graft surgery

                  394 (13.2)

                  116 (12.1)

                  205 (13.5)

                  73 (14.2)

                  0.44

                  83 (7.3)

                  34 (7.8)

                  33 (7.3)

                  16 (6.3)

                  0.77

                  <0.01

                  Extent of coronary artery disease at baseline as assessed by coronary angiography, n (%)

                        

                  No significant coronary artery disease

                  538 (18.0)

                  179 (17.7)

                  280 (18.5)

                  88 (17.2)

                  0.77

                  492 (43.1)

                  197 (45.2)

                  187 (41.3)

                  108 (42.7)

                  0.50

                  <0.001

                  1-vessel disease

                  704 (23.6)

                  218 (22.7)

                  373 (24.6)

                  113 (22.0)

                  0.38

                  254 (22.2)

                  88 (20.2)

                  109 (24.1)

                  57 (22.5)

                  0.38

                  0.37

                  2-vessel disease

                  731 (24.5)

                  236 (24.6)

                  360 (23.7)

                  135 (26.3)

                  0.50

                  192 (16.8)

                  72 (16.5)

                  80 (17.7)

                  40 (15.8)

                  0.80

                  <0.001

                  3-vesseldisease

                  1016 (34.0)

                  335 (34.9)

                  504 (33.2)

                  177 (34.5)

                  0.66

                  204 (17.9)

                  79 (18.1)

                  77 (17.0)

                  48 (19.0)

                  0.79

                  <0.001

                  Comorbidity at baseline, n (%)

                           

                  Pulmonary disease

                  276 (9.2)

                  96 (10.0)

                  115 (7.6)

                  65 (12.7)

                  0.04

                  91 (8.0)

                  43 (9.9)

                  25 (5.5)

                  23 (9.1)

                  <0.01

                  0.20

                  Cancer

                  4 (0.1)

                  2 (0.20)

                  1 (0.10)

                  1 (0.20)

                  0.59

                  0 (0.0)

                  0

                  0

                  0

                  -

                  0.22

                  Medication following baseline coronary angiography, n (%)

                         

                  Acetylsalisylic acid

                  2546 (85.2)

                  810 (84.5)

                  1306 (86.1)

                  430 (83.8)

                  0.13

                  830 (72.7)

                  304 (69.7)

                  332 (73.3)

                  194 (76.7)

                  0.34

                  <0.001

                  Statins

                  2492 (83.4)

                  759 (79.1)

                  1296 (85.4)

                  437 (85.2)

                  <0.001

                  818 (71.6)

                  305 (70.0)

                  330 (72.8)

                  183 (72.3)

                  0.61

                  <0.001

                  β-blockers

                  2229 (74.6)

                  684 (71.3)

                  1155 (76.1)

                  390 (76.0)

                  0.02

                  765 (67.0)

                  286 (65.6)

                  301 (66.4)

                  178 (70.4)

                  0.42

                  <0.001

                  ACE inhibitors

                  644 (21.5)

                  171 (17.8)

                  320 (21.1)

                  153 (29.8)

                  <0.001

                  214 (18.7)

                  72 (16.2)

                  83 (18.3)

                  59 (23.3)

                  0.08

                  0.05

                  Loop diuretics

                  297 (9.9)

                  90 (9.4)

                  128 (8.4)

                  79 (15.4)

                  <0.001

                  150 (13.1)

                  37 (8.5)

                  54 (11.9)

                  59 (23.3)

                  <0.001

                  <0.01

                  Coronary revascularization following baseline coronary angiography, n (%)

                        

                  Percutaneous coronary intervention

                  1065 (35.6)

                  327 (34.1)

                  545 (35.9)

                  193 (37.6)

                  0.38

                  283 (24.8)

                  105 (24.1)

                  118 (26.0)

                  60 (23.7)

                  0.72

                  <0.001

                  Coronary artery bypass graft surgery

                  731 (24.5)

                  248 (25.9)

                  363 (23.9)

                  120 (23.4)

                  0.46

                  161 (14.1)

                  54 (12.4)

                  75 (16.6)

                  32 (12.6)

                  0.15

                  <0.001

                  Biochemical markers

                            

                  Creatinine (μmol/L)

                  96.4 (31.7)

                  96.6 (30.5)

                  96.4 (34.9)

                  95.9 (23.3)

                  0.93

                  82.8 (26.5)

                  83.9 (36.7)

                  81.4 (14.5)

                  83.4 (21.5)

                  0.35

                  <0.001

                  eGFR (mL/min)

                  89.3 (17.0)

                  87.5 (16.6)

                  89.7 (16.6)

                  91.2 (16.9)

                  <0.001

                  84.1 (17.3)

                  83.4 (17.6)

                  84.6 (16.1)

                  84.2 (18.7)

                  0.58

                  <0.001

                  CRP (mg/L)

                  3.66 (7.59)

                  3.55 (8.91)

                  3.58 (6.99)

                  4.07 (6.49)

                  0.39

                  3.79 (5.93)

                  2.88(5.17

                  3.62 (5.43)

                  5.66 (7.42)

                  <0.001

                  0.59

                  Glucose (mmol/L)

                  6.41 (2.38)

                  6.08 (2.42)

                  6.33 (2.14)

                  7.26 (2.77)

                  <0.001

                  6.20 (2.46)

                  5.60 (1.75)

                  6.30 (2.68)

                  7.06 (2.82)

                  <0.001

                  0.01

                  HbA1c (mmol/L)

                  6.17 (1.39)

                  6.16 (1.11)

                  6.40 (1.52)

                  6.62 (1.49)

                  <0.001

                  6.36 (1.38)

                  6.10 (1.36)

                  6.11 (1.37)

                  6.46 (1.43)

                  <0.001

                  <0.001

                  Hemoglobin (g/dL)

                  14.6 (1.16)

                  14.2 (1.21)

                  14.7 (1.07)

                  14.8 (1.16)

                  <0.001

                  13.4 (1.05)

                  13.3 (1.04)

                  13.5 (1.04)

                  13.5 (1.05)

                  <0.01

                  <0.001

                  ApoA1 (g/L)

                  1.26 (0.25)

                  1.31 (0.27)

                  1.25 (0.23)

                  1.20 (0.23)

                  <0.001

                  1.46 (0.27)

                  1.49 (0.28)

                  1.45 (0.26

                  1.42 (0.27)

                  <0.01

                  <0.001

                  ApoB (g/L)

                  0.90 (0.25)

                  0.86 (0.24)

                  0.90 (0.24)

                  0.93 (0.27)

                  <0.001

                  0.92 (0.25)

                  0.88 (0.24)

                  0.94 (0.26)

                  0.94 (0.25)

                  <0.01

                  <0.01

                  Total cholesterol (mmol/L)

                  4.98 (1.17)

                  5.18 (1.12)

                  5.39 (1.14)

                  5.25 (1.16)

                  0.30

                  5.28 (1.14)

                  5.18 (1.12)

                  5.39 (1.14)

                  5.25 (1.16)

                  0.02

                  <0.001

                  LDL cholesterol (mmol/L)

                  3.05 (1.02)

                  3.03 (1.01)

                  3.06 (0.98)

                  3.07 (1.13)

                  0.64

                  3.19 (1.03)

                  3.08 (1.02)

                  3.30 (1.03)

                  3.18 (1.04)

                  <0.01

                  <0.001

                  HDL cholesterol (mmol/L)

                  1.22 (0.33)

                  1.33 (0.38)

                  1.19 (0.29)

                  1.09 (0.26)

                  <0.001

                  1.47 (0.42)

                  1.57 (0.44)

                  1.45 (0.39)

                  1.34 (0.37)

                  <0.001

                  <0.001

                  Triglycerides (mmol/L)

                  1.85 (1.28)

                  1.48 (0.97)

                  1.91 (1.30)

                  2.32 (1.52)

                  <0.001

                  1.62 (1.03)

                  1.34 (0.72)

                  1.67 (1.18)

                  2.00 (1.07)

                  <0.001

                  <0.001

                  Lp(a) (mmol/L)

                  0.41 (0.37)

                  0.43 (0.41)

                  0.48 (0.45)

                  0.47 (0.40)

                  0.79

                  0.46 (0.42)

                  0.43 (0.41)

                  0.48 (0.45)

                  0.47 (0.40)

                  0.11

                  <0.01

                  WENBIT intervention trial, n (%)

                  2047 (68.5)

                  614 (64.0)

                  1072 (70.7)

                  361 (70.4)

                  <0.01

                  513 (44.9)

                  183 (42.0)

                  211 (46.6)

                  119 (47.0)

                  0.29

                  <0.001

                  B6, n (% of WENBIT participants)

                  1043 (34.9)

                  320 (52.1)

                  553 (51.9)

                  170 (47.1)

                  0.19

                  239 (20.9)

                  89 (48.6)

                  96 (45.5)

                  54 (45.4)

                  0.94

                  <0.001

                  Folate/B12, n (% of WENBIT participants)

                  1031 (34.5)

                  301 (49.0)

                  555 (51.8)

                  175 (48.5)

                  0.03

                  244 (21.4)

                  93 (50.8)

                  102 (48.3)

                  49 (41.2)

                  0.92

                  <0.001

                  ACE, angiotensin converting enzyme; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, body mass index; CRP, c-reactive protein; eGFR, esitimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; Lp(a), lipoprotein (a).

                  aNormal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2).

                  bBased on differences between BMI groups among men, and was calculated by ANOVA for continuous variables and Chi squared test for categorical variables for differences between men and women.

                  cBased on differences between BMI groups among women, and was calculated by ANOVA for continuous variables and Chi squared test for categorical variables for differences between men and women.

                  dBased on between group differences in men vs. women, and was calculated by independent samples t-test for continuous variables and Chi squared test for categorical variables.

                  eMean (SD).

                  fIncludes DM type 1 and 2.

                  gSmokers included self-reported current smoking, those who quit smoking within <1 month and patients with plasma cotinine >85 ng/mL.

                  hPatients reported to have quit smoking > 1 month prior to inclusion.

                  iIncluded those reporting to have at least one 1st degree relative suffering from CAD before the age of 55 for men and 65 for women.

                  Follow-up and end-points

                  During the follow-up period (mean (SD) 4.8 (1.4) years), 337 (8.2%) patients experienced an AMI, of which 101 (30%) were fatal. A total of 302 (7.3%) patients died, of whom 165 (55%) died from cardiovascular causes.

                  There were statistically significant multivariate adjusted interactions between gender and BMI categories with regards to risk of incident AMI (p-int = 0.011) and CV-death (p-int = 0.031), but not to all-cause mortality (p-int = 0.427).

                  A total of 115 (8.2%) normal weight patients, 127 (6.4%) overweight patients and 60 (7.8%) obese patients died. The risk of all-cause mortality did not differ significantly between BMI categories in any analyses; compared to the normal weight group, the multivariate adjusted HR (95% CI) was 0.95 (0.74, 1.23) in the overweight group and 1.16 (0.84, 1.60) in the obese group.

                  Analyses were repeated in subgroups of patients with significant CAD or without diabetes only, and the results were not significantly different from those reported (data not shown).

                  Gender stratified analyses

                  A total of 267 (8.9%) men and 70 (6.1%) women suffered an AMI. Further, 241 (8.1%) men and 61 (5.3%) women died, whereof 132 (55%) male deaths and 33 (54%) female deaths were characterised as CV deaths.

                  Obese men had a significantly higher multivariate adjusted risk of both incident AMI; HR 1.80 (1.28, 2.52), and CV death; HR 1.60 (1.00, 2.55), compared to normal weight men (Table  3).
                  Table 3

                  BMI groups a and risk of acute myocardial infarction and cardiovascular death in men

                  Model

                  Acute myocardial infarction

                  Cardiovascular death

                   

                  Events, n (%)

                  HR

                  95% CI

                  p-value

                  Events, n (%)

                  HR

                  95% CI

                  p-value

                  Univariate

                          

                  Normal weight

                  84 (8.8)

                  1.00

                    

                  51 (5.3)

                  1.00

                    

                  Overweight

                  117 (7.7)

                  0.88

                  0.66, 1.16

                  0.37

                  49 (3.2)

                  0.61

                  0.41, 0.90

                  0.01

                  Obese

                  66 (12.9)

                  1.51

                  1.09, 2.08

                  0.01

                  32 (6.2)

                  1.19

                  0.76, 1.85

                  0.45

                  Multivariate adjusted b

                         

                  Normal weight

                  1.00

                     

                  1.00

                    

                  Overweight

                  1.11

                  0.84, 1.48

                  0.47

                   

                  0.85

                  0.57, 1.28

                  0.44

                  Obese

                  1.80

                  1.28, 2.52

                  <0.01

                   

                  1.60

                  1.00, 2.55

                  0.05

                  BMI, body mass index; CI, confidence interval; HR, hazard ratio.

                  aNormal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2).

                  bAge (continuous), current smoking (yes/no), left ventricular ejection fraction (%), pulmonary disease (yes/no), angiotensin converting enzyme-inhibitors (yes/no) and loop diuretics (yes/no).

                  Overweight women had a significantly lower multivariate adjusted risk of AMI; HR 0.56 (0.33, 0.98), compared to normal weight women (Table  4). By contrast, the multivariate adjusted HR for AMI between normal weight women and obese women did not differ significantly.
                  Table 4

                  BMI groups a and risk of acute myocardial infarction and cardiovascular death in women

                  Model

                  Acute myocardial infarction

                  Cardiovascular death

                   

                  Events, n (%)

                  HR

                  95% CI

                  p-value

                  Events, n (%)

                  HR

                  95% CI

                  p-value

                  Univariate

                          

                  Normal weight

                  33 (7.6)

                  1.00

                    

                  16 (3.7)

                  1.00

                    

                  Overweight

                  21 (4.6)

                  0.61

                  0.35, 1.05

                  0.08

                  13 (2.9)

                  0.78

                  0.38, 1.63

                  0.51

                  Obese

                  16 (6.3)

                  0.84

                  0.46, 1.53

                  0.57

                  4 (1.6)

                  0.43

                  0.14, 1.28

                  0.13

                  Multivariate adjusted b

                         

                  Normal weight

                  1.00

                     

                  1.00

                    

                  Overweight

                   

                  0.56

                  0.33, 0.98

                  0.04

                   

                  0.71

                  0.34, 1.50

                  0.37

                  Obese

                   

                  0.80

                  0.43, 1.47

                  0.46

                   

                  0.38

                  0.21, 1.16

                  0.09

                  BMI, body mass index; CI, confidence interval; HR, hazard ratio.

                  a Normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2).

                  b Age (continuous), current smoking (yes/no), left ventricular ejection fraction (%), pulmonary disease (yes/no), angiotensin converting enzyme-inhibitors (yes/no) and loop diuretics (yes/no).

                  Discussion

                  Principal findings

                  In this large longitudinal prospective cohort study of more than 4000 patients with suspected stable angina pectoris, we demonstrate that obese male patients had a 1.8 fold and 1.6 fold increased risk of incident AMI and CV death compared to normal weight men. By contrast, compared to normal weight women, obese women had similar risk of AMI and CV death, while overweight women had nearly half the risk of incident AMI. The risk of all-cause mortality associated with BMI was similar among men and women, and did not differ significantly across BMI categories.

                  BMI and risk of AMI, CV death and all-cause mortality in men and women

                  Strong associations between overweight/obesity and risk of CVD and death have been demonstrated in the general population [19, 20]. By contrast, several studies of patients with CAD have demonstrated that overweight and/or obese patients may have a better morbidity and mortality prognosis than their leaner counterparts; although as one recent review points out, this observation is not supported by all [3].

                  Only a few studies of patients with CAD have examined the association between BMI and risk of CV events and mortality in men and women separately. Our finding of an increased risk of cardiovascular events among obese men are in accordance with the results from a previous US study of patients with stable CVD, whereof 85% had CHD, as well as with a multi-ethnic sample study of patients with established CAD [5, 6]. However, while these studies did not observe any significant associations between BMI and risk of major adverse coronary events in women, we report a nearly halved adjusted risk of AMI among overweight women as compared to their normal weight counterparts.

                  In the present study, there was no interaction between BMI and gender with regards to all-cause mortality. Moreover, the risk of death did not differ between BMI groups. These findings are in accordance with a previous study conducted among European patients with CAD [21]. To the best of our knowledge only two studies, of patients with CAD, have examined the association between BMI and all-cause mortality in men and women separately [7, 8]. First, a study of Danish patients with AMI showed that normal weight, overweight and obese men had similar risk of death, whereas overweight women had a slightly decreased risk (HR (95% CI); 0.78 (0.68, 0.90)) of death, as compared to their normal weight counterparts. Furthermore, in a follow up study of the CADILLAC trial, they observed significantly lower in-hospital mortality (0.9% vs. 2.7%), 30 days (1.1% vs. 3.8%) and 1- year (1.8% vs. 7.5%) mortality in obese patients with AMI undergoing PCI when compared to normal weight patients. Statistical significance was, however, only reached in males.

                  Possible explanations

                  BMI is often used to quantify overweight and obesity owing to a high fat percentage correlation, but does not account for fat distribution. Men have a tendency to store excessive fat in visceral fat deposits, whereas women usually store fat in peripheral subcutaneous distributions [4]. Excessive visceral fat is associated with an increased risk of developing metabolic syndrome, putting men at a greater risk of developing CVD, while subcutaneous fat in the femoral-gluteal region may be associated with a more favourable CV risk profile [22]. Furthermore, overweight and obese postmenopausal women may benefit from the increase in circulating levels of estrogen produced by the adipose tissue [23, 24].

                  Moreover, at baseline, men were more often affected by CV risk factors and had more severe CAD. Inclusion of these potential confounding variables in stratified multivariate analyses did not alter our results. Differing health status at baseline is thus unlikely to be the cause of the observed gender interaction.

                  Strengths and limitations of the study

                  The main strength of the present study is its, well defined population with complete follow up of clinical endpoints. Limitations include the single baseline measurements of BMI and other time dependent cofactors such as medication. We did not have sufficient data on possible confounders such as physical activity, socioeconomic status or cardio- respiratory fitness and intentional vs. unintentional weight loss, and thus we cannot exclude the possibility that residual confounding from unmeasured causal factors unevenly distributed between BMI groups may have influenced our results. Unfortunately, we did not have data on recent weight loss prior to inclusion, but as underweight patients (BMI <18.5 kg/m2) were excluded, and adjustment for possible confounders such as cancer, pulmonary disease, extent of significant CAD and LVEF did not significantly alter our results, reverse causation is unlikely. BMI was positively associated with common obesity related characteristics such as higher blood pressure, diabetes, an unfavourable lipid profile, higher eGFR and CRP. Adjustment for these variables did not have a significant effect on our results, but we would in any case not include these variables in a final multivariate adjusted survival model because of the possibility of over-adjustment bias. We did, however, adjust for use of ACE inhibitors and loop diuretics as a proxy of heart failure, and there is the possibility that these variables may have mediated some of the effect of BMI.

                  It has previously been suggested that BMI is an inadequate marker of overweight and obesity in patients with CAD [25], with waist circumference or waist to hip ratio suggested as better predictors of cardiovascular events, especially in women [6, 26]. Studies supporting an obesity paradox have almost exclusively used BMI as an index of obesity [3]. We thus suspect that the diverging findings among such studies may be the result of BMI’s inadequacy as a quantifier of true body fatness and fat distribution.

                  Given that there were relatively few females in the study population and the event rate was low, we thus had a low statistical power to by which to detect the possible effects of BMI on risk of events among women. Further, we cannot rule out that the relatively lower incidence rate of AMI among women is a result of detection bias; women, compared to men, are more likely to experience atypical symptoms of AMI and may consequently delay seeking medical care for symptoms or be misdiagnosed by healthcare providers [27]. Finally, the inclusion of predominantly white subjects limits the ability to generalise our findings to non-white populations.

                  Conclusion

                  Among 4131 men and women with suspected stable angina pectoris, obese men carried an 80% and 60% higher risk of AMI and CV death, respectively, compared to normal weight men, whereas being overweight, compared to normal weight, was associated with a 50% lower risk of AMI among women. These findings may potentially explain some of the result variation in studies reporting on the obesity paradox, with further investigation of the interaction between gender and BMI in terms of risk of CV events and mortality therefore warranted.

                  Declarations

                  Acknowledgements

                  We thank all WENBIT coworkers at Haukeland and Stavanger University Hospitals, Norway, as well as the Endpoints Committee: Marta Ebbing (HUS), Leik Woie (SUS), Eva Ringdal Pedersen (UiB), Hall Schartum-Hansen (UiB), Per Lund Johansen (UiB) (Chair). We would also like to thank all those who participated in the study for their time and effort. Thanks are also due to Matthew McGee for proofreading the manuscript.

                  Authors’ Affiliations

                  (1)
                  Morbid Obesity Center, Vestfold Hospital Trust
                  (2)
                  Institute of Clinical Medicine, University of Oslo
                  (3)
                  Department of Clinical Science, University of Bergen
                  (4)
                  Department of Heart Disease, Haukeland University Hospital

                  References

                  1. The top 10 causes of death http://​www.​who.​int/​mediacentre/​factsheets/​fs310/​en/​
                  2. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson J, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013.
                  3. Chrysant SG, Chrysant GS: New insights into the true nature of the obesity paradox and the lower cardiovascular risk. J Am Soc Hypertens 2013,7(1):85–94.PubMedView Article
                  4. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres JP: Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr 1993,58(4):463–467.PubMed
                  5. Domanski MJ, Jablonski KA, Rice MM, Fowler SE, Braunwald E, Investigators P: Obesity and cardiovascular events in patients with established coronary disease. Eur Heart J 2006,27(12):1416–1422.PubMedView Article
                  6. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S: Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005,149(1):54–60.PubMedView Article
                  7. Kragelund C, Hassager C, Hildebrandt P, Torp-Pedersen C, Kober L: Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol 2005,98(1):123–131.PubMedView Article
                  8. Nikolsky E, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Negoita M, Lansky AJ, Mehran R: Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. Am Heart J 2006,151(1):168–175.PubMedView Article
                  9. Wessel TR, Arant CB, Olson MB, Johnson BD, Reis SE, Sharaf BL, Shaw LJ, Handberg E, Sopko G, Kelsey SF, Pepine CJ, Merz NB: Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA 2004,292(10):1179–1187.PubMedView Article
                  10. Svingen GF, Ueland PM, Pedersen EK, Schartum-Hansen H, Seifert R, Ebbing M, Loland KH, Tell GS, Nygard O: Plasma dimethylglycine and risk of incident acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol 2013.
                  11. Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygard O: Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008,300(7):795–804.PubMedView Article
                  12. Benowitz NL, Jacob P III, Ahijevych K, Jarvis MJ, Hall S, LeHouezec J, Hansson A, Henningfield J, Tsoh J, Hurt RD, Velicer W for the The SRNT Subcommittee on Biochemical Verification: Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002,4(2):149–159.View Article
                  13. Midttun O, Hustad S, Ueland PM: Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2009,23(9):1371–1379.PubMedView Article
                  14. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972,18(6):499–502.PubMed
                  15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009,150(9):604–612.PubMed CentralPubMedView Article
                  16. Alpert JS, Antman E, Apple F, Beller G, Breithardt G, Armstrong PW, Bassand JP, Baye´s de Luna A, Chaitman BR, Clemmensen P, Falk E, Fishbein MC, Galvani M, Garson A Jr, Grines C, Hamm C, Hoppe U, Jaffe A, Katus H, Kjekshus J, Klein W, Klootwijk P, Lenfant C, Levy D, Levy RI, Luepker R, Marcus F, Näslund U, Ohman M, Pahlm O, et al.: Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000,21(18):1502–1513.View Article
                  17. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM, Simoons ML, Van De Werf FJJ, Weintraub WS, Mitchell KR, Morrisson SL, Anderson HV, Cannom DS, Chitwood WR, Cigarroa JE, Collins-Nakai RL, Gibbons RJ, Grover FL, Heidenreich PA, Khandheria BK, Knoebel SB, Krumholz HL, Malenka DJ, Mark DB, Mckay CR, Passamani ER, Radford MJ, et al.: American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001,38(7):2114–2130.PubMedView Article
                  18. Greenland S: Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989,79(3):340–349.PubMed CentralPubMedView Article
                  19. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999,100(13):1481–1492.PubMedView Article
                  20. Eckel RH: Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee. Am Heart Assoc Circul 1997,96(9):3248–3250.
                  21. De Bacquer D, De Backer G, Ostor E, Simon J, Pyorala K, Group EIS: Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort. Eur J Cardiovasc Prev Rehabil 2003,10(4):289–295.PubMedView Article
                  22. Snijder MB, van Dam RM, Visser M, Seidell JC: What aspects of body fat are particularly hazardous and how do we measure them? Int J Epidemiol 2006,35(1):83–92.PubMedView Article
                  23. Silva TC, Barrett-Connor E, Ramires JA, Mansur AP: Obesity, estrone, and coronary artery disease in postmenopausal women. Maturitas 2008,59(3):242–248.PubMedView Article
                  24. Castracane VD, Kraemer GR, Ogden BW, Kraemer RR: Interrelationships of serum estradiol, estrone, and estrone sulfate, adiposity, biochemical bone markers, and leptin in post-menopausal women. Maturitas 2006,53(2):217–225.PubMedView Article
                  25. Romero-Corral A, Somers VK, Sierra-Johnson J, Jensen MD, Thomas RJ, Squires RW, Allison TG, Korinek J, Lopez-Jimenez F: Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease. Eur Heart J 2007,28(17):2087–2093.PubMedView Article
                  26. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE: Abdominal adiposity and coronary heart disease in women. JAMA 1998,280(21):1843–1848.PubMedView Article
                  27. Maas AH, van der Schouw YT, Regitz-Zagrosek V, Swahn E, Appelman YE, Pasterkamp G, Ten Cate H, Nilsson PM, Huisman MV, Stam HC, Eizema K, Stramba-Badiale M: Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. Eur Heart J 2011,32(11):1362–1368.PubMedView Article
                  28. Pre-publication history

                    1. The pre-publication history for this paper can be accessed here: http://​www.​biomedcentral.​com/​1471-2261/​14/​68/​prepub

                  Copyright

                  © Borgeraas et al.; licensee BioMed Central Ltd. 2014

                  This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.